# US 5,716,613 A · Recombinant retroviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,716,613 A
- Document ID: US5716613A
- Status: Granted
- Kind: A
- Application number: 08/474,736
- Filed: 1995-06-07
- Granted: 1998-02-10
- Earliest claimed: 1988-03-21
- Assignees: Chiron Viagene, Inc.
- Inventors: Harry E. Guber; Douglas J. Jolly; James G. Respess; Paul K. Laikind
- Web page: https://patentgrep.com/patent/US5716613A

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C07K 14/005: from viruses
- C07K 14/70514: {CD4}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C12N 15/86: Viral vectors
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13023: Virus like particles [VLP]
- C12N 2740/13032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/13052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16023: Virus like particles [VLP]
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising a physiologically acceptable carrier or diluent and a replication-defective recombinant retrovirus construct which directs the expression of at least one viral or cancer antigen or mutated form thereof eliciting a cell-mediated immune response directed to said viral or cancer antigen or mutated form thereof within a human, and wherein said vital antigen is from a virus pathogenic to humans.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein the expressed antigen elicits an HLA class I-restricted immune response.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 wherein the expressed antigen is an HIV protein or mutated form thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein said cancer antigen is selected from the group consisting of a cervical carcinoma antigen, a leukemia antigen, a prostate cancer antigen, a colon cancer antigen, and a melanoma antigen.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein said cancer antigen is selected from the group consisting of an HPV antigen, an HTLV I antigen, prostate specific antigen, mutated p53 protein, and GD 2 antigen.

### Claim 6 (depends on 2)

The pharmaceutical composition of claim 2 wherein the expressed antigen elicits an HLA Class II-restricted immune response.

### Claim 7 (depends on 3)

The pharmaceutical composition of claim 3, wherein the HIV protein is an HIV envelope protein.